Venus Remedies Receives First US Patent for Vancoplus

OUR BUREAU
CHANDIGARH

Drug company Venus Remedies on Thursday announced its first US patent from US PTO for its research product Vancoplus valid up to December 2027.

The company now is gearing to launch the product in the US market and has already bagged patents from South Africa, New Zealand and Ukraine.

Venus is also eying the countries like Canada, Europe, Russia, Mexico, Brazil and Japan for the product and intends to out-licence Vancoplus across patent protected regions to major pharmaceutical players. "Vancoplus is the most effective and safe option available to curb the notorious MRSA strain. The Vancoplus therapy is not only cost effective but it also reduces treatment time and is a boon for the medical field," joint managing director and director research, Venus Remedies, Manu Chaudhary, said.

She added that the Institute of Medicine (IOM) in US has also estimated that the financial burden of anti-microbial resistance (including direct and indirect costs) may be as high as $30 billion per year and as per a report, majority of the people in US die from hospital acquired staph infection (MRSA) than AIDS.



Venus is also eying the countries like Canada, Europe, Russia, Mexico, Brazil and Japan for the product

Vancoplus, a brand of Ceftriaxone and Vancomycin along with a chemical vector, used in CVMC technology, is the only remedy after vaccination to treat MRSA and multi-drug resistant microbes which causes Meningitis, Pneumonia, Typhoid, Septicemia, urinary tract infection, skin infections and Staphylococcal Endocarditis.

The drug restricts the production of toxin by MRSA pathogens and also reduces the treatment time, cost and adverse effects.